SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Synthetic Drug Con-
trol Act of 2011’’. 
SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 
OF THE CONTROLLED SUBSTANCES ACT. 
(a) CANNABIMIMETIC AGENTS.—Schedule I, as set 
forth in section 202(c) of the Controlled Substances Act 
(21 U.S.C. 812(c)) is amended by adding at the end the 
following: 
‘‘(d)(1) Unless specifically exempted or unless listed 
in another schedule, any material, compound, mixture, or 
preparation 
which 
contains 
any 
quantity 
of 
cannabimimetic agents, or which contains their salts, iso-
mers, and salts of isomers whenever the existence of such 
salts, isomers, and salts of isomers is possible within the 
specific chemical designation. 
‘‘(2) In paragraph (1): 
‘‘(A) The term ‘cannabimimetic agents’ means 
any substance that is a cannabinoid receptor type 1 
(CB1 receptor) agonist as demonstrated by binding 
studies and functional assays within any of the fol-
lowing structural classes: 
‘‘(i) 
2-(3-hydroxycyclohexyl)phenol 
with 
substitution at the 5-position of the phenolic 
ring by alkyl or alkenyl, whether or not sub-
stituted on the cyclohexyl ring to any extent.
‘‘(ii) 
3-(1-naphthoyl)indole 
or 
3-(1- 
naphthylmethane)indole by substitution at the 
nitrogen atom of the indole ring, whether or not 
further substituted on the indole ring to any ex-
tent, whether or not substituted on the naph-
thoyl or naphthyl ring to any extent. 
‘‘(iii) 3-(1-naphthoyl)pyrrole by substi-
tution at the nitrogen atom of the pyrrole ring, 
whether or not further substituted in the 
pyrrole ring to any extent, whether or not sub-
stituted on the naphthoyl ring to any extent. 
‘‘(iv) 
1-(1-naphthylmethylene)indene 
by 
substitution of the 3-position of the indene ring, 
whether or not further substituted in the indene 
ring to any extent, whether or not substituted 
on the naphthyl ring to any extent. 
‘‘(v) 
3-phenylacetylindole 
or 
3- 
benzoylindole by substitution at the nitrogen 
atom of the indole ring, whether or not further 
substituted in the indole ring to any extent, 
whether or not substituted on the phenyl ring 
to any extent. 
‘‘(B) Such term includes— 
‘‘(i) 
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- 
hydroxycyclohexyl]-phenol (CP–47,497);
‘‘(ii) 
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- 
hydroxycyclohexyl]-phenol (cannabicyclohexanol 
or CP–47,497 C8-homolog); 
‘‘(iii) 
1-pentyl-3-(1-naphthoyl)indole 
(JWH–018 and AM678); 
‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH– 
073); 
‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH– 
019); 
‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph-
thoyl)indole (JWH–200); 
‘‘(vii) 
1-pentyl-3-(2- 
methoxyphenylacetyl)indole (JWH–250); 
‘‘(viii) 
1-pentyl-3-[1-(4- 
methoxynaphthoyl)]indole (JWH–081); 
‘‘(ix) 
1-pentyl-3-(4-methyl-1-naph-
thoyl)indole (JWH–122); 
‘‘(x) 
1-pentyl-3-(4-chloro-1-naph-
thoyl)indole (JWH–398); 
‘‘(xi) 
1-(5-fluoropentyl)-3-(1-naph-
thoyl)indole (AM2201); 
‘‘(xii) 
1-(5-fluoropentyl)-3-(2- 
iodobenzoyl)indole (AM694); 
‘‘(xiii) 
1-pentyl-3-[(4-methoxy)-ben-
zoyl]indole (SR–19 and RCS–4);
‘‘(xiv) 
1-cyclohexylethyl-3-(2- 
methoxyphenylacetyl)indole (SR–18 and RCS– 
8); and 
‘‘(xv) 
1-pentyl-3-(2- 
chlorophenylacetyl)indole (JWH–203).’’. 
(b) OTHER DRUGS.—Schedule I of section 202(c) of 
the Controlled Substances Act (21 U.S.C. 812(c)) is 
amended in subsection (c) by adding at the end the fol-
lowing: 
‘‘(18) 4-methylmethcathinone (Mephedrone). 
‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV). 
‘‘(20) 
3,4-methylenedioxymethcathinone 
(methylone). 
‘‘(21) Naphthylpyrovalerone (naphyrone). 
‘‘(22) 4-fluoromethcathinone (flephedrone). 
‘‘(23) 4-methoxymethcathinone (methedrone; 
Bk–PMMA). 
‘‘(24) Ethcathinone (N-Ethylcathinone). 
‘‘(25) 
3,4-methylenedioxyethcathinone 
(ethylone). 
‘‘(26) 
Beta-keto-N-methyl-3,4- 
benzodioxyolybutanamine (butylone). 
‘‘(27) 
N,N-dimethylcathinone 
(metamfepramone).
‘‘(28) Alpha-pyrrolidinopropiophenone (alpha- 
PPP). 
‘‘(29) 
4-methoxy-alpha- 
pyrrolidinopropiophenone (MOPPP). 
‘‘(30) 
3,4-methylenedioxy- 
alphapyrrolidinopropiophenone (MDPPP). 
‘‘(31) Alpha-pyrrolidinovalerophenone (alpha- 
PVP). 
‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol- 
6-amine) (MDAI). 
‘‘(33) 3-fluoromethcathinone. 
‘‘(34) 
4’-Methyl-α-pyrrolidinobutiophenone 
(MPBP). 
‘‘(35) 
2-(2,5-Dimethoxy-4- 
ethylphenyl)ethanamine (2C–E). 
‘‘(36) 
2-(2,5-Dimethoxy-4- 
methylphenyl)ethanamine (2C–D). 
‘‘(37) 
2-(4-Chloro-2,5- 
dimethoxyphenyl)ethanamine (2C–C). 
‘‘(38) 
2-(4-Iodo-2,5- 
dimethoxyphenyl)ethanamine (2C–I). 
‘‘(39) 
2-[4-(Ethylthio)-2,5- 
dimethoxyphenyl]ethanamine (2C–T–2). 
‘‘(40) 
2-[4-(Isopropylthio)-2,5- 
dimethoxyphenyl]ethanamine (2C–T–4).
‘‘(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C– 
H). 
‘‘(42) 
2-(2,5-Dimethoxy-4-nitro- 
phenyl)ethanamine (2C–N). 
‘‘(43) 
2-(2,5-Dimethoxy-4-(n)- 
propylphenyl)ethanamine (2C–P).’’. 
SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 
HAZARDS TO PUBLIC SAFETY EXPANSION. 
Section 201(h)(2) of the Controlled Substances Act 
(21 U.S.C. 811(h)(2)) is amended— 
(1) by striking ‘‘one year’’ and inserting ‘‘2 
years’’; and 
(2) by striking ‘‘six months’’ and inserting ‘‘1 
year’’. 
Passed the House of Representatives December 8, 
2011. 
Attest: 
Clerk.
112TH CONGRESS 
1ST SESSION 
H. R. 1254 
AN ACT 
To amend the Controlled Substances Act to place 
synthetic drugs in Schedule I.